BioCentury | May 4, 2018
Financial News

Unity prices $85M IPO

...molecule targets the interaction between mdm2 p53 binding protein homolog (MDM2; HDM2) and p53. Unity's UBX1967...
...C round in March (see BioCentury, March 23) . Unity Biotechnology Inc. (NASDAQ:UBX), Brisbane, Calif. Brian Moy UBX0101 UBX1967 Unity...
BioCentury | May 2, 2018
Financial News

Unity prices $85M IPO

...molecule targets the interaction between mdm2 p53 binding protein homolog (MDM2; HDM2) and p53. Unity's UBX1967...
...closed a $55 million series C round in March (see BioCentury Extra, March 19) . Brian Moy UBX0101 UBX1967 Unity...
BioCentury | Apr 13, 2018
Financial News

Unity proposes $85M IPO

...molecule targets the interaction between mdm2 p53 binding protein homolog (MDM2; HDM2) and p53. Unity's UBX1967...
BioCentury | Apr 6, 2018
Financial News

Age-related disease play Unity planning IPO

...molecule targets the interaction between mdm2 p53 binding protein homolog (MDM2; HDM2) and p53. Unity's UBX1967...
...see BioCentury Extra, April 25, 2016) . Unity's investors also include China-based 6 Dimensions Capital. Paul Bonanos UBX0101 UBX1967 Unity...
BioCentury | Mar 23, 2018
Financial News

Unity raises $55M series C

...HDM2) and p53, is expected to enter the clinic this half to treat osteoarthritis. Unity's UBX1967...
BioCentury | Mar 19, 2018
Financial News

Unity raises $55M series C

...HDM2) and p53, is expected to enter the clinic this half to treat osteoarthritis. Unity's UBX1967...
Items per page:
1 - 6 of 6